Details for New Drug Application (NDA): 205197
✉ Email this page to a colleague
The generic ingredient in PLERIXAFOR is plerixafor. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the plerixafor profile page.
Summary for 205197
Tradename: | PLERIXAFOR |
Applicant: | Teva Pharms Usa Inc |
Ingredient: | plerixafor |
Patents: | 0 |
Pharmacology for NDA: 205197
Physiological Effect | Increased Hematopoietic Stem Cell Mobilization |
Suppliers and Packaging for NDA: 205197
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
PLERIXAFOR | plerixafor | SOLUTION;SUBCUTANEOUS | 205197 | ANDA | Teva Pharmaceuticals, Inc. | 0480-4320 | 0480-4320-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (0480-4320-01) / 1.2 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 24MG/1.2ML (20MG/ML) | ||||
Approval Date: | Jul 24, 2023 | TE: | AP | RLD: | No |
Complete Access Available with Subscription